Research Blog
The Metabolic Trifecta Explained: Retatrutide, NAD+ and MOTS-c Compared
Published
Retatrutide, NAD+ and MOTS-c act at three different layers of metabolic research. What each one is, how they differ, and how each vial is reconstituted.

For laboratory research use only. This article describes research compounds as they appear in the published preclinical literature. It contains no dosing, human-use, veterinary, or clinical guidance and makes no health or benefit claims.
The Metabolic Trifecta groups three research compounds that share almost nothing mechanistically, and that is the point of the kit. Retatrutide acts at the cell surface, as an agonist at three receptors: GIP, GLP-1 and glucagon. NAD+ acts inside the cell, as a coenzyme for redox reactions and a substrate for enzymes such as sirtuins and PARPs. MOTS-c is a peptide encoded in mitochondrial DNA, studied as a signal from the mitochondria to the rest of the cell. Three layers of metabolic research, three non-redundant tools, supplied as three separate vials.
Three pathway layers, one kit
Metabolic research spans several biological layers: receptor signalling at the cell surface, cofactor availability inside the cell, and signalling from the mitochondria themselves. Each compound in the kit maps onto one of those layers, and none substitutes for either of the others. A design that needs to touch more than one layer gets three independent entry points instead of three variations on one mechanism.
Retatrutide: triple receptor agonism at the cell surface
Retatrutide (LY3437943, listed on this site as GLP-3 RT) is a synthetic peptide engineered to engage three receptors of the incretin and glucagon family at once: GIP, GLP-1 and glucagon. That distinguishes it from single-receptor and dual-receptor agonists, and it is used in research models comparing combined receptor engagement with narrower agonism. Its receptor pharmacology and early preclinical and clinical profile were described in a 2022 paper in Cell Metabolism. More detail is in the retatrutide research overview.
NAD+: a redox cofactor, not a receptor ligand
NAD+ (nicotinamide adenine dinucleotide, molecular weight 663.43 Da) is not a peptide and does not act at a receptor. It is a coenzyme central to redox reactions and cellular energy metabolism, and more recent literature also treats it as a consumed substrate for sirtuins and PARPs, whose activity depends on how much NAD+ is available. Where retatrutide research asks what happens when a receptor is engaged, NAD+ research more often asks what happens when cellular NAD+ levels change. See NAD+ in cellular research.
MOTS-c: a peptide encoded in mitochondrial DNA
MOTS-c is a 16-residue peptide encoded within the mitochondrial genome rather than the nuclear genome, an unusual origin among research peptides. The 2015 study in Cell Metabolism that characterised it reported activity through the AMPK pathway in cell and mouse models. It is used to study communication between mitochondria and the rest of the cell, a layer that neither a surface receptor agonist nor a diffusible coenzyme addresses directly. The discovery of MOTS-c covers its background.
Side-by-side comparison
| Retatrutide | NAD+ | MOTS-c | |
|---|---|---|---|
| Molecular class | Synthetic multi-receptor agonist peptide | Dinucleotide coenzyme | Mitochondrial-DNA-encoded peptide |
| Where it acts | Cell surface: GIP, GLP-1 and glucagon receptors | Intracellular: redox reactions; sirtuin and PARP substrate | Mitochondria-to-cell signalling; AMPK pathway |
| Molecular weight | Large peptide (several kDa) | 663.43 Da | About 2.17 kDa |
| Vial in the kit | Retatrutide vial | 1000 mg | 40 mg |
What the literature does and does not cover
Each compound has its own independent literature. No published study has evaluated retatrutide, NAD+ and MOTS-c together as a three-part protocol, so a design using the kit is combining three separately characterised tools rather than following an established combination. Because the three act on different pathways, designs generally track outcome measures specific to each pathway rather than a single combined endpoint. The MOTS-c vs NAD+ comparison covers the two mitochondrial-research tools in more depth.
Reconstitution: three vials, three different solvents
The three vials are reconstituted and logged separately, and they do not all take the same solvent:
- Retatrutide: bacteriostatic water.
- MOTS-c: does not fully dissolve in plain bacteriostatic water and is usually reconstituted with an acetic acid solution.
- NAD+: its listing specifies sterile saline for in-vitro work. At 1000 mg, the vial holds far more material than a peptide vial, so check solubility and fill capacity before choosing a volume.
The formula is the same for each: concentration (mg/mL) = vial mass (mg) ÷ volume added (mL). The ratio chart covers every vial size, and the calculator handles the larger volumes. Log each vial's solvent, volume, concentration and date separately.
Storage
Keep all three dry vials cold, dark and dry until use. Once reconstituted, refrigerate the solutions at 2–8 °C and protect them from light. A large peptide, a small-molecule cofactor and a short peptide do not share one stability profile, so track time since reconstitution for each vial separately; the storage guide covers the general rules.
Frequently Asked Questions
Does the Metabolic Trifecta ship as one combined vial?
No. It ships as three separate vials, retatrutide, NAD+ and MOTS-c, each reconstituted on its own with the solvent it needs.
Do retatrutide, NAD+ and MOTS-c share a mechanism?
No. Retatrutide acts on cell-surface receptors, NAD+ works inside the cell as a cofactor and enzyme substrate, and MOTS-c is a mitochondrial-derived signalling peptide. They act at three distinct layers, which is why they are grouped.
Is there published research on the three together?
No. Each has its own independently published literature; the combination has not been studied as a single protocol.
Further reading
- Retatrutide research overview: the triple agonist in depth.
- MOTS-c vs NAD+: two approaches in mitochondrial research.
- The discovery of MOTS-c: how a mitochondrial-DNA-encoded peptide was found.
For laboratory and research use only. Not for human or animal consumption.
Related research compounds
Compounds referenced in this article, available as research-grade lyophilized peptides with third-party tested COA.
